AstraZeneca to build manufacturing sites in Guangzhou and Shanghai
The British pharmaceutical company AstraZeneca has announced plans to establish production facilities in Guangzhou and Shanghai, as well as a separate innovation centre in Shanghai. These projects are part of its $15 billion investment programme running through 2030.
Source South China Morning Post
In Guangzhou, AstraZeneca will build a plant to produce next-generation radioconjugate drugs for cancer treatment. These drugs target cancer cells with precision and will include actinium-225-based treatments for prostate cancer.
In Shanghai's Lingang district, the company will create a base for manufacturing CAR-T cell therapy — an innovative cancer treatment where a patient’s own immune cells are reprogrammed to fight cancer. Additionally, an innovation centre will be established in the Pudong district to boost AstraZeneca’s research capabilities.
AstraZeneca, founded in 1999, is a global British biopharmaceutical corporation specialising in the development, manufacture, and marketing of medicines, especially in oncology, cardiovascular, and respiratory diseases.
The $15 billion investment through 2030 underlines AstraZeneca’s commitment to strengthening its presence in China and advancing cutting-edge cancer therapies, highlighting China’s growing role in the global biopharmaceutical industry.
Looking forward, these manufacturing developments are expected to improve the availability of innovative treatments in China and reinforce AstraZeneca’s position in the global pharmaceutical market.
